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Abstract
Purpose
To investigate the usefulness of meibomian gland (MG) dropout rate in the evaluation of MG
morphological change associated with the use of prostaglandin for glaucoma treatment
through the association between MG and the ocular surface parameters and medication
duration and presence of preservative.
Methods
This cross-sectional study was conducted on 88 eyes of 88 patients who were diagnosed
with glaucoma and used only Tafluprost as treatment. The patients were divided into four
“user” groups: 1) 23 patients used preservative-free (PF) Tafluprost for 6 months; 2) 21
patients used preservative-containing (PC) Tafluprost for 6 months; 3) 23 patients used PF-
Tafluprost for 24 months; 4) 21 patients used PC-Tafluprost for 24 months. Ocular surface
parameters and the MG condition, including MG dropout rate and meiboscale, were evalu-
ated. Multiple regression was used to identify associations.
Results
There were significant differences in age (p = 0.003), tear breakup time (p = 0.016), lid mar-
gin abnormality (p = 0.016), expressibility (p = 0.039), meiboscale (p<0.001), and MG drop-
out rate (p<0.001) among the 4 groups. MG dropout rate and meiboscale showed significant
differences in all post hoc analyses, except for the comparison between the PF-Tafluprost
and PC-Tafluprost 6-month user groups. Medication duration, preservative status, and mei-
boscale were significantly correlated with MG dropout rate (p<0.001, p = 0.024, p<0.001,
respectively). In the 6-month user group, preservative status significantly correlated with
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MG dropout rate (p = 0.015). However, in the 24-month user group, meiboscale was the
only parameter significantly associated with MG dropout rate (p<0.001).
Conclusion
MG dropout rate in patients using Tafluprost showed a significant correlation with medica-
tion duration and preservative status. This result indicates MG dropout rate reflects MG mor-
phologic change associated with prostaglandin.
Introduction
Glaucoma is an irreversible progressive disorder of the optic nerve, which can cause blindness
if not properly treated. Treatment of glaucoma comprises reduction of intraocular pressure
(IOP), which can be achieved with eye drops or laser or surgical methods; however, the pri-
mary treatment method is the use of anti-glaucoma eye drops. Continuous use of topical anti-
glaucoma medications is necessary to maintain the IOP-lowering effect. A notable limitation
in this approach is that long-term use of topical anti-glaucoma medications increases the risk
of developing ocular surface diseases [1–5]. Several previous studies have shown that the high
incidence of dry eye, as well as the deterioration of ocular parameters and meibomian gland
dysfunction (MGD) in glaucoma patients using IOP-lowering eyedrops is associated with the
use of topical anti-glaucoma medications [6–10]. Previously, we also reported that glaucoma
patients using topical anti-glaucoma medications showed deterioration of ocular surface sta-
tus, including reduction in the thickness of the tear lipid layer [11].
Meibomian gland (MG) condition in glaucoma patients is related to the behaviors involved
in medication use, such as frequency and duration, as well as the type of preservative and active
ingredient in the medication [6,7,9,10,12]. Among several active ingredients used as topical
anti-glaucoma medications, prostaglandin analogues (PGAs) are known to be associated with
development of MGD [8,9,13–15]. Because MGD worsens the condition of the ocular surface
[16], an indicator is needed to objectively evaluate MG status in PGA users.
MG dropout rate is an objective parameter that reflects morphologic changes of the MG,
indicating loss of the gland. Unlike hyperkeratinization of the MG duct, MG dropout is more
closely associated with MG atrophy, suggesting underlying MGD [17,18]. Several previous
studies have shown the usefulness of the MG dropout rate for evaluating MGD associated with
cataract surgery or periocular radiotherapy [19,20].
Therefore, we conducted this study to evaluate the usefulness of the MG dropout rate for
assessing MG status in glaucoma patients using topical PGAs. We analyzed the correlation
between medication factors including medication duration and presence or absence of preser-
vative and parameters for ocular surface and MG status, including MG dropout rate. Among
topical PGAs, we only used preservative-containing (PC) and preservative-free (PF) Tafluprost
(Taflotan and Taflotan-S, Santen Pharmaceutical Co. Ltd., Osaka, Japan) to minimize the
effect of medication differences.
Materials and methods
This cross-sectional study was conducted in the Department of Ophthalmology, Severance
Hospital, Yonsei University School of Medicine (Seoul, Korea), and followed the tenets of the
Declaration of Helsinki. Ethical approval was obtained from the Institutional Review Board of
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Severance Hospital, Yonsei University College of Medicine, Seoul, Korea; written informed
consent was obtained from all subjects who enrolled in the study. By retrospectively reviewing
medical records from the period between January 2015 and December 2017, we identified 88
patients who met the inclusion criteria. The patients were diagnosed with glaucoma for the
first time in our glaucoma clinic and began using topical PC- or PF-Tafluprost, which has
been used as one of standard treatment methods to treat glaucoma patients in our institution.
To the included patients who had no change or addition of topical anti-glaucoma medications
during the follow-up period, ophthalmic examinations were performed cross-sectionally at the
6- or 24-month follow-up visit. Patients with a history of ocular surgery, ocular injury, or dis-
ease affecting the ocular surface and MG such as allergic conjunctivitis or demodex on eye-
lashes, as well as patients using other topical agents (e.g., topical steroids, non-steroidal anti-
inflammatory drugs, or artificial tears) were excluded in the process of reviewing the medical
records of patients. This was confirmed again directly with the patients who visited the outpa-
tient clinic at 6 or 24 months after topical Tafluprost use. In addition, ocular surface and lid
margin status were also evaluated at the time of visiting the outpatient clinic to exclude
patients having conditions affecting the ocular surface and MG. Among the included patients,
we evaluated the ocular surface and MG status in patients who used the medication for 6
months and those who used the medication for 24 months. Included patients did not have
abnormal findings regarding the MG or ocular surface conditions in the medical records of
their first visit.
Forty-four eyes of 44 glaucoma patients who used topical Tafluprost for 6 months and 44
eyes of 44 glaucoma patients who used topical Tafluprost for 24 months were included in the
present study. In each group, 23 eyes of 23 patients used PF-Tafluprost and the remaining 21
eyes of 21 patients used PC-Tafluprost.
As a control group, we enrolled 64 eyes of 64 subjects who visited our hospital for regular
check-up or preoperative examination associated with refractive surgery or cataract surgery by
reviewing medical records retrospectively. For these subjects, the same examinations for ocular
surface and MG conditions were conducted.
Evaluation of MG and ocular surface status
Ocular surface and MG conditions were evaluated using the same methods as described in pre-
vious studies published by ophthalmologists from our institution [11,19,21]. Tear lipid layer
thickness (LLT) and MG images of the lower lid (to assess MG dropout rate) were acquired
using the LipiView II system (Tear Science, Morrisville, NY, USA). The measurement unit
used for LLT was interferometric color units (ICUs), where 1 ICU represented 1 nm of LLT.
Among maximum ICU, minimum ICU, and average ICU, average ICU was used. The MG
dropout rate in the lower lid was calculated using a previously described method [19]. By auto-
matic threshold identification in the ImageJ software (US National Institutes of Health,
Bethesda, MD, USA), the numbers of pixels indicative of total MG area and MG structure area
were calculated. Dropout rate was calculated using the following formula: MG dropout rate =
[1- (MG structure area / Total MG area)]. Morphologic change of MG was also evaluated
using the meiboscale. As previously described, meiboscale is another method for assessing the
morphologic change with a score from 0 to 4 points where each point represents a 25% reduc-
tion in MG area (0: no reduction, 1: 25% reduction, 2: 50% reduction, 3: 75% reduction, and 4:
100% reduction).
Through direct observation using slit-lamp microscopy, assessments of lid margin abnor-
mality, meibum quality, and meibum expressibility were conducted. Lid margin abnormality
was scored from 0 to 4 on the basis of four factors: vascular engorgement, plugging of the MG
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orifice, anterior or posterior displacement of the mucocutaneous junction, and irregularity of
the lid margin. Eight lower lid glands were assessed using a scale of 0 to 3 points at each gland
for meibum quality (score range from 0 to 24; grade 0: clear, grade 1: cloudy, grade 2: cloudy
with granular debris, and grade 3: thick, like toothpaste). Expressibility of MG was scored by
applying digital pressure on five glands of the central one-third of the lower lid, with a score
range from 0 to 3 (0: all five glands expressible, 1: three to four glands expressible, 2: one to
two glands expressible, 3: no glands expressible).
Tear break up time (TBUT) using a fluorescein strip, type I Schirmer test, and ocular sur-
face staining score (Oxford score) were used to assess ocular surface condition. The ocular sur-
face disease index (OSDI) was used to evaluate subjective ocular discomfort. As described
previously [19], the examinations were conducted in the order of LLT measurement and
acquiring MG images of the lower lid using the LipiView II system, TBUT, Oxford score, lid
margin abnormality, meibum quality, meibum expressibility, OSDI, and Schirmer test to min-
imize the influence of each examination on the other assessments. All examinations were con-
ducted by two experienced examiners (K.L. and S.K.). Of two eyes in each patient, we included
the eye in which the subject complained of greater discomfort. If the degree of discomfort was
similar in both eyes, the right eye was selected for inclusion in the present study.
Statistical analysis
For comparison of continuous and categorical parameters between the groups, the indepen-
dent two-sample t-test, analyses of variance, and chi-squared tests were performed. A multi-
variate regression analysis was used to investigate correlations among parameters showing
significant differences in group comparisons, including age, sex, medication duration, and
presence or absence of preservative in the medication (preservative status). In addition, a mul-
tivariate regression analysis was used to identify factors correlated with MG dropout rate on
the basis of medication duration and preservative status. All statistical analyses were performed
using SAS version 9.4 software (SAS Institute Inc., Cary, NC, USA). Statistical significance was
defined as p<0.05.
Results
Table 1 shows the results of comparisons between non-glaucoma subjects and glaucoma
patients using Tafluprost. There were no significant differences in age and sex ratio between
the two groups. All parameters for ocular surface and MG condition showed significant differ-
ences, except meiboscale.
We compared age, sex ratio, ocular surface parameters, and MG parameters among four
groups: 1) 6-month users of PF-Tafluprost; 2) 6-month users of PC-Tafluprost; 3) 24-month
users of PF-Tafluprost; and 4) 24-month users of PC-Tafluprost. There were significant differ-
ences in age (p = 0.003), TBUT (p = 0.016), lid margin abnormality (p = 0.016), expressibility
(p = 0.039), meiboscale (p<0.001), and MG dropout rate (p<0.001) among the four groups
(Table 2). Results of post hoc analyses are shown in Fig 1. There were significant differences in
age between 6-month users of PF-Tafluprost and 6-month users of PC-Tafluprost (p = 0.045),
as well as between 6-month users of PF-Tafluprost and 24-month users of PC-Tafluprost
(p = 0.003). TBUT showed a significant difference only between 24-month users of PF-Taflu-
prost and 24-month users of PC-Tafluprost (p = 0.022). There were significant differences
between 6-month users of PF-Tafluprost and 24-month users of PC-Tafluprost in lid margin
abnormality and expressibility (p = 0.048 and p = 0.022, respectively). MG dropout rate and
meiboscale showed significant differences in all post hoc analyses, except for comparisons
between 6-month users of PF-Tafluprost and 6-month users of PC-Tafluprost.
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TBUT, lid margin abnormality, expressibility, meiboscale, and MG dropout rate showed
significant differences in comparisons among the groups. Correlations among these parame-
ters were identified by multiple regression analyses including age, sex, medication duration,
and preservative status (Table 3). TBUT was significantly correlated with preservative status
(p = 0.005). Age and expressibility were significantly correlated with lid margin abnormality
(p = 0.004 and p = 0.023, respectively). Expressibility was significantly correlated with age
(p = 0.003), sex (p = 0.04), lid margin abnormality (p = 0.023), and meiboscale (p<0.001).
Table 1. Comparison of clinical variables and parameters indicative of ocular surface and meibomian gland conditions between control and glaucoma patients
using Tafluprost.
Control (N = 64)
(Mean ± SD or Ratio)
Glaucoma using Tafluprost (N = 88)
(Mean ± SD or Ratio)
p�
Age (years) 52.91 ± 20.95 50.77 ± 14.67 0.461
Sex (M:F) 29:35 45:43 0.478
OD:OS 43:21 54:34 0.461
LLT (ICU) 82.50 ± 20.39 68.88 ± 24.19 <0.001
TBUT (s) 6.70 ± 3.78 4.95 ± 2.98 0.002
Dye staining 0.29 ± 0.39 1.17 ± 0.95 <0.001
Schirmer (mm) 12.09 ± 7.97 9.14 ± 5.05 0.005
OSDI 9.86 ± 9.27 26.68 ± 19.96 <0.001
Lid margin abnormality 1.17 ± 1. 1.67 ± 1.15 0.006
Meibum quality 6.03 ± 4.89 9.84 ± 5.92 <0.001
Expressibility 0.58 ± 0.69 1.05 ± 0.91 0.001
Meiboscale 1.19 ± 0.91 1.39 ± 0.95 0.197
MG dropout rate 0.396 ± 0.08 0.434 ± 0.11 0.023
� Independent t-test or chi-squared test. LLT, lipid layer thickness; TBUT, tear breakup time; OSDI, ocular surface disease index; MG, meibomian gland
https://doi.org/10.1371/journal.pone.0218886.t001
Table 2. Comparison of clinical variables and parameters indicative of ocular surface and meibomian gland condition among study groups using Tafluprost.
6 M (N = 44) 24 M (N = 44)
PF-Tafluprost (N = 23)
(Mean ± SD or Ratio)
PC-Tafluprost (N = 21)
(Mean ± SD or Ratio)
PF-Tafluprost (N = 23)
(Mean ± SD or Ratio)
PC-Tafluprost (N = 21)
(Mean ± SD or Ratio)
p�
Age (years) 43.17 ± 11.87 54.24 ± 14 48.43 ± 15.59 58.19 ± 13.24 0.003
Sex (M:F) 11:12 9:12 14:9 11:10 0.668
OD:OS 12:11 16:5 14:9 12:9 0.403
ICU 65.7 ± 23.41 68 ± 22.62 70.61 ± 22.22 71.33 ± 29.43 0.863
TBUT (s) 5.13 ± 2.85 4.19 ± 2.36 6.43 ± 3.94 3.90 ± 1.64 0.018
Dye staining 1 ± 0.97 0.93 ± 1.21 1.13 ± 0.97 1.27 ± 0.83 0.218
Schirmer (mm) 8.35 ± 4.89 9.86 ± 4.08 7.78 ± 5.01 10.76 ± 5.86 0.186
OSDI 27.99 ± 22.26 30.16 ± 23.54 24.96 ± 13.19 23.66 ± 20.35 0.715
Lid margin abnormality 1.22 ± 1.09 2.05 ± 1.28 1.39 ± 0.94 2.10 ± 1.09 0.016
Meibum quality 7.83 ± 5.85 10.95 ± 5.84 8.70 ± 5.87 12.20 ± 5.44 0.053
Expressibility 0.7 ± 0.82 1 ± 1 1.04 ± 1.02 1.48 ± 0.6 0.039
Meiboscale 0.739 ± 0.541 0.762 ± 0.625 1.70 ± 0.82 2.38 ± 0.67 <0.001
MG dropout rate 0.335 ± 0.59 0.380 ± 0.0484 0.473 ± 0.09 0.555 ± 0.1 <0.001
� Analysis of variance or chi-squared test. PF, preservative-free; PC, preservative-containing; LLT, lipid layer thickness; TBUT, tear breakup time; OSDI, ocular surface
disease index; MG, meibomian gland
https://doi.org/10.1371/journal.pone.0218886.t002
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Three parameters showed significant correlations with MG dropout rate: medication duration,
preservative status, and meiboscale (p<0.001, p = 0.024, and p<0.001, respectively). Meibos-
cale showed significant correlations with medication duration (p = 0.003), expressibility
(p = 0.037), and MG dropout rate (p<0.001).
MG dropout rate was the only parameter in the multiple regression analyses that was
correlated with both medication duration and preservative status. Table 4 shows the
results of the multiple regression analyses to investigate correlations between MG
dropout rate and other parameters in each subgroup, stratified by mediation duration
and preservative status. In the 6-month user group, only preservative status showed a sig-
nificant correlation with MG dropout rate (p = 0.015). However, in the 24-month user
group, meiboscale was the only parameter significantly correlated with MG dropout rate
(p<0.001). In the PC-Tafluprost user group, only meiboscale was significantly correlated
with MG dropout rate (p<0.001). However, medication duration and meiboscale were sig-
nificantly correlated with MG dropout rate among users of PF-Tafluprost (p = 0.002 and
p = 0.007, respectively).
Fig 1. Comparisons of ocular surface and meibomian gland parameters among subgroups. The Tukey method was
used as a post hoc analysis after analysis of variance. � indicates significant difference in post hoc analysis. LLT, lipid
layer thickness; TBUT, tear breakup time; OSDI, ocular surface disease index; MG, meibomian gland.
https://doi.org/10.1371/journal.pone.0218886.g001
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Discussion
Because of their ease of use (once per day) and strong IOP-lowering effects, PGAs have been
used as a first-choice medication for treatment of glaucoma [22,23]. Therefore, it is important
to evaluate the alteration of MG condition associated with PGAs because MG-related disease
can affect medication compliance [24, 25]. Recently, PF-PGAs have been developed, which
can be used to reduce the occurrence of ocular surface disorder and MGD associated with the
preservatives in topical medications. However, because the active ingredient present in PGAs
is associated with the onset of MGD, deterioration of MG status is unavoidable during long-
term medication use, even when using PF-PGAs. In the present study, among parameters
indicative of ocular surface and MG condition, TBUT, lid margin abnormality score, meibum
quality score, meiboscale, and MG dropout rate showed at least one significant difference in
group comparisons (Fig 1A and 1B). Among these parameters, MG dropout rate and meibos-
cale showed a stepwise increasing pattern and significant differences in nearly all comparisons
between subgroups. This suggests that the methods for evaluating the deterioration of MG
morphology can be used as a way of identifying the negative effect of the preservatives
included in the PGAs or the negative effect of the duration of PGAs use.
Table 3. Correlations between clinical variables and parameters indicative of ocular surface and meibomian gland condition.
TBUT Lid margin abnormality Expressibility MG Dropout rate Meiboscale
Age β 0.02 0.03 0.02 0.001 -0.01
(95% CI) (-0.03 to 0.08) (0.01 to 0.04) (0.01 to 0.03) (-0.001 to 0.002) (-0.02 to 0.01)
P 0.419 0.004 0.003 0.253 0.447
Sex β -0.27 0.17 -0.47 0.001 0.06
(male reference) (95% CI) (-1.61 to 1.06) (-0.26 to 0.6) (-0.78 to -0.16) (-0.03 to 0.03) (-0.2 to 0.32)
P 0.687 0.43 0.04 0.931 0.654
Duration β 0.25 -0.34 -0.06 0.08 0.54
(6M reference) (95% CI) (-1.67 to 2.17) (-0.95 to 0.27) (-0.53 to 0.41) (0.04 to 0.12) (0.19 to 0.89)
P 0.799 0.271 0.793 < .001 0.003
Preservative β -2.05 0.36 -0.08 0.04 0.01
(non-preservative reference) (95% CI) (-3.48 to -0.62) (-0.12 to 0.83) (-0.44 to 0.29) (0.01 to 0.07) (-0.29 to 0.3)
P 0.005 0.14 0.685 0.024 0.964
TBUT β 0.02 -0.02 0.001 0.01
(95% CI) (-0.05 to 0.09) (-0.08 to 0.03) (-0.01 to 0.01) (-0.03 to 0.06)
P 0.561 0.447 0.895 0.6
Lid margin abnormality β 0.2 0.19 -0.003 0.09
(95% CI) (-0.49 to 0.9) (0.03 to 0.36) (-0.02 to 0.01) (-0.05 to 0.23)
P 0.561 0.023 0.681 0.19
Expressibility β -0.35 0.33 -0.003 0.19
(95% CI) (-1.26 to 0.56) (0.05 to 0.62) (-0.02 to 0.02) (0.01 to 0.36)
P 0.447 0.023 0.767 0.037
MG dropout rate β -0.66 -0.65 -0.36 4.26
(95% CI) (-10.49 to 9.18) (-3.81 to 2.5) (-2.77 to 2.05) (2.58 to 5.94)
P 0.895 0.681 0.767 < .001
Meiboscale β 0.3 0.24 0.06 0.06
(95% CI) (-0.84 to 1.44) (-0.12 to 0.61) (0.04 to 0.08) (0.04 to 0.08)
P 0.6 0.188 < .001 < .001
TBUT, tear breakup time; MG, meibomian gland
https://doi.org/10.1371/journal.pone.0218886.t003
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In the present study, MG dropout rate was significantly correlated with medication dura-
tion and preservative status, when the data were adjusted for age and sex. Notably, MG drop-
out rate was significantly correlated with preservative status in 6-month user group; however,
there was no significant correlation between preservative status and MG dropout rate in the
24-month user group. Considering the results of another subgroup analysis conducted under a
different preservative status in the present study, which showed a significant correlation
between MG dropout rate and medication duration only in the PF-Tafluprost user group, MG
dropout rate may represent morphologic changes in the MG that are affected by preservative
status and medication duration. Meiboscale, another parameter indicative of morphologic
changes of the MG, showed correlation results that were similar to those exemplified by MG
dropout rate. However, multivariate analyses showed that preservative status was not corre-
lated with meiboscale; thus, the effect of preservative on MG may not be accurately reflected
by meiboscale. Several previous studies indicated that MG loss was affected by age and sex
[26–28]. However, because we showed that MG dropout rate was correlated with the duration
of Tafluprost use and preservative status, regardless of age and sex, the MG dropout rate may
be useful for evaluating MGD status in glaucoma patients using PC- or PF-PGAs.
A number of previous studies have reported that PF anti-glaucoma topical medications
have advantages in treatment of ocular surface disease [29–32]. Tear film instability, caused by
detergent effects, direct toxicity, and allergic reactions, is a known mechanism of preservative-
induced ocular surface disease [29,33–35]. In addition, the induction of chronic inflammation
by this mechanism increases the occurrence of MGD [36]. However, if the active ingredient
induces MGD, the benefit of using a PF medication may be limited. Our findings support this
conclusion.
The MG dropout rate and meiboscale among 24-month users of PF-Tafluprost were higher
than those among 6-month users of PC-Tafluprost. In addition, the MG dropout rate was sig-
nificantly correlated with the presence of preservative only in patients who used Tafluprost for
Table 4. Correlations between MG dropout rate and other parameters based on medication duration or preservative status.
6 M (N = 44) 24 M (N = 44) PC-Tafluprost (N = 42) PF-Tafluprost (N = 46)
β (95% CI) P� β (95% CI) P� β (95% CI) P� β (95% CI) P�
Age < .001 0.709 0.001 0.493 0.001 0.226 < .001 0.613
(-0.001 to 0.002) (-0.001 to 0.003) (-0.001 to 0.003) (-0.001 to 0.002)
Sex 0.002 0.901 < .001 0.999 0.03 0.165 -0.02 0.385
(male reference) (-0.04 to 0.04) (-0.05 to 0.05) (-0.01 to 0.08) (-0.07 to 0.03)
Duration 0.07 0.076 0.09 0.002
(6M reference) (-0.01 to 0.14) (0.03 to 0.14)
Preservative 0.05 0.015 0.02 0.555
(non-preservative reference) (0.01 to 0.09) (-0.04 to 0.08)
TBUT 0.01 0.111 -0.003 0.458 0.004 0.435 -0.001 0.834
(-0.001 to 0.01) (-0.01 to 0.01) (-0.01 to 0.02) (-0.01 to 0.01)
Lid margin abnormality -0.001 0.952 0.01 0.939 -0.01 0.551 -0.01 0.678
(-0.02 to 0.02) (-0.03 to 0.03) (-0.03 to 0.02) (-0.03 to 0.02)
Expressibility -0.004 0.95 -0.01 0.782 -0.01 0.615 0.01 0.739
(-0.003 to 0.01) (-0.04 to 0.03) (-0.04 to 0.03) (-0.03 to 0.04)
Meiboscale 0.02 0.273 0.08 < .001 0.07 < .001 0.05 0.007
(-0.02 to 0.05) (0.04 to 0.11) (0.03 to 0.11) (0.01 to 0.08)
�Multiple regression. PC, preservative-containing; PF, preservative-free; TBUT, tear breakup time; MG, meibomian gland
https://doi.org/10.1371/journal.pone.0218886.t004
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6 months. These results support the possibility that PF-PGAs may exhibit a limited prevention
effect on the development and progression of MGD. However, this limited prevention effect is
not an indication that PF-PGAs have no clinical use. Rather, it suggests that PF-PGAs should
be the primary consideration when using PGAs in glaucoma patients who have already begun
to exhibit atrophic changes in the MG. According to our results, MG dropout rate can be used
to identify the glaucoma patients who should use PF-PGAs preferentially by measuring objec-
tive status of MG. Further studies are needed to define the cut-off value of MG dropout rate
for determining whether PF-PGAs are required.
To investigate the effect of topical anti-glaucoma medication on the ocular surface and MG
condition, behavior regarding medication use (e.g., instillation frequency, medication dura-
tion, and compliance) as well as the type or concentration of active ingredient and preserva-
tive, should be well-controlled. However, it is difficult to conduct research in which these
conditions are well-controlled in clinical practice. Therefore, specific formulas, such as burden
of anti-glaucoma score, were used to assess the effects of different anti-glaucoma medications
in a previous study [6]. We conducted the present study by using only Tafluprost among
PGAs. In this manner, we were able to compare changes in the ocular surface and MG condi-
tion according to preservative status and medication duration, using a similar active ingredient
type, concentration, and instillation frequency. Although we could not identify the precise
level of compliance for Tafluprost use in individual patients, we could assume that compliance
of Tafluprost was not low, given that this medication required instillation once per day, and
that these patients used the same medication (without any changes or addition of new medica-
tions) because of the stability of IOP. Therefore, the results of our study were conducted in a
condition where confounding factors were controlled as much as possible, which contributes
to a high degree of reliability. Based on the results of our study, further analyses are needed to
confirm the usefulness of the MG dropout rate for assessment of morphologic alterations in
the MG when using other types of anti-glaucoma medications (i.e., non-PGAs).
This study has several limitations. First, we could not confirm the longitudinal change of
the MG dropout rate because this study used a cross-sectional design. By performing longitu-
dinal follow-up of the same patients included in this study, patterns of change in MG dropout
rate might be identified. Second, we could not evaluate primary conditions of MG and ocular
surface in included patients, although we excluded patients whose medical records described
abnormal MG findings. Lastly, only Korean patients were included in this study. Because the
reported MGD prevalence in the Asian population is higher than that in the Western popula-
tion [37,38], additional studies are needed to characterize the usefulness of MG dropout rate
on various ethnicities.
In conclusion, MG dropout rate in patients using Tafluprost was significantly correlated
with medication duration and preservative status. Considering the changing pattern and cor-
relation of MG dropout rate with preservative status and medication duration, MG dropout
rate could be used to assess MG status in users of PC-Tafluprost or PF-Tafluprost. This result
could be applied to users of other PGAs in addition to Tafluprost.
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